Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme (Q81615619)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18616418%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

review article

1 reference

title

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18616418%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18616418%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

4

Tom Mikkelsen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18616418%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

David A Reardon

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18616418%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Roger Stupp

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18616418%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

1 August 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18616418%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

10 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18616418%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18616418%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18616418%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

1225-1235

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18616418%20AND%20SRC:MED&resulttype=core&format=json

Molecular signaling mechanisms of cell migration and invasion

10 January 2020

cites work

1 reference

12 December 2020

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

1 reference

12 December 2020

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

1 reference

12 December 2020

Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist

1 reference

12 December 2020

Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery.

1 reference

12 December 2020

Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins

1 reference

12 December 2020

Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo

1 reference

12 December 2020

Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.

1 reference

12 December 2020

alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.

1 reference

12 December 2020

Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts

1 reference

12 December 2020

Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin

1 reference

12 December 2020

Get a ligand, get a life: integrins, signaling and cell survival

1 reference

12 December 2020

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

1 reference

12 December 2020

alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.

1 reference

12 December 2020

RGDS peptide induces caspase 8 and caspase 9 activation in human endothelial cells

1 reference

12 December 2020

Characterization of integrin receptors in normal and neoplastic human brain.

1 reference

12 December 2020

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

12 December 2020

Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue.

1 reference

12 December 2020

An antagonist of integrin αvβ3 prevents maturation of blood vessels during embryonic neovascularization

1 reference

12 December 2020

Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta1 integrins.

1 reference

12 December 2020

Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases

1 reference

12 December 2020

Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors.

1 reference

12 December 2020

Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides

1 reference

12 December 2020

The role of integrins in the malignant phenotype of gliomas

1 reference

12 December 2020

Astrocytoma adhesion to extracellular matrix: functional significance of integrin and focal adhesion kinase expression

1 reference

12 December 2020

N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists

1 reference

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

12 December 2020

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

12 December 2020

Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy

1 reference

12 December 2020

Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist

1 reference

12 December 2020

Angiogenesis in gliomas: biology and molecular pathophysiology

1 reference

12 December 2020

Integrins: molecular targets in cancer therapy

1 reference

12 December 2020

Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models

1 reference

12 December 2020

Molecular mediators of alphavbeta3-induced endothelial cell survival

1 reference

12 December 2020

Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells

1 reference

12 December 2020

Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice

1 reference

12 December 2020

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

1 reference

12 December 2020

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

1 reference

12 December 2020

Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro

1 reference

12 December 2020

Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors

1 reference

12 December 2020

The biology of integrins

1 reference

12 December 2020

1 reference

12 December 2020

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

1 reference

12 December 2020

Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761.

1 reference

12 December 2020

Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.

1 reference

12 December 2020

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

12 December 2020

10.1517/13543784.17.8.1225

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18616418%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18616418%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

PubMed publication ID

18616418

1 reference